Efficacy and Safety Comparisons of Four Approved Chimeric Antigen Receptor T-Cell Therapies in Multiple Myeloma - PubMed
a day ago
- #CAR T-cell therapy
- #multiple myeloma
- #BCMA-targeting
- Multiple myeloma (MM) remains incurable despite advances in novel therapies due to inevitable relapse.
- Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable efficacy in relapsed/refractory (R/R) MM.
- Four B-cell maturation antigen (BCMA)-targeting CAR T-cell therapies are approved in the U.S. and China for R/R MM: idecabtagene vicleucel, ciltacabtagene autoleucel, equecabtagene autoleucel, and zevorcabtagene autoleucel.
- A comprehensive comparative analysis of the efficacy and toxicity profiles of these four CAR T-cell therapies is lacking.
- This review compares the efficacy and safety of the four approved BCMA-directed CAR T-cell therapies.
- Potential factors underlying observed differences are discussed, along with strategies to improve clinical outcomes.